Brian Savage - 04 Mar 2026 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
Interim Chief Legal Officer
Signature
/s/ Dov Bergwerk as attorney-in-fact for Brian P. Savage
Issuer symbol
TEVA
Transactions as of
04 Mar 2026
Net transactions value
-$86,843
Form type
4
Filing time
06 Mar 2026, 16:03:56 UTC
Previous filing
05 Mar 2026
Next filing
09 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Savage Brian Interim Chief Legal Officer C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A STREET, TEL AVIV, ISRAEL /s/ Dov Bergwerk as attorney-in-fact for Brian P. Savage 06 Mar 2026 0002112339

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TEVA Ordinary Shares Options Exercise +4,744 +162% 7,670 04 Mar 2026 Direct F1, F2
transaction TEVA Ordinary Shares Sale $48,340 -1,489 -19% $32.46 6,181 04 Mar 2026 Direct F1, F3, F4
transaction TEVA Ordinary Shares Options Exercise +3,466 +56% 9,647 04 Mar 2026 Direct F1, F2
transaction TEVA Ordinary Shares Sale $38,503 -1,186 -12% $32.46 8,461 04 Mar 2026 Direct F1, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Restricted Share Units Options Exercise -4,744 -100% $0.000000* 0 04 Mar 2026 Ordinary Shares 4,744 Direct F1, F2, F5
transaction TEVA Restricted Share Units Options Exercise -3,766 -33% $0.000000* 7,534 04 Mar 2026 Ordinary Shares 3,766 Direct F1, F2, F6
transaction TEVA Restricted Share Units Award +11,280 $0.000000* 11,280 04 Mar 2026 Ordinary Shares 11,280 Direct F1, F2, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.095 to $33.30, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5 Restricted share units were granted on March 4, 2022, with 4,741 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 4,744 vested on March 4, 2026.
F6 Restricted share units were granted on March 4, 2024, with 3,766 vested on each of March 4, 2025 and March 4, 2026, 3,766 vesting on March 4, 2027, and 3,768 vesting on March 4, 2028.
F7 Restricted share units were granted on March 4, 2026, with 2,820 vesting on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030.